• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Dec. 16, 2011

View Archived Issues

'BLOOM' off the Rose: LibiGel Failure Sends BioSante Falling

BioSante Pharmaceuticals Inc., of Lincolnshire, Ill., reported disappointing results from its two pivotal Phase III trials of LibiGel (testosterone gel) for hypoactive sexual desire disorder in postmenopausal women. Read More

Post-ASH, Ariad Prices Public Offering, Aims to Raise $224M

On Wednesday, Ariad Pharmaceuticals Inc. filed a shelf registration covering stock, debt securities, warrants and units. The company didn't leave investors in suspense for long. A day later, the company priced an underwritten public offering of 21.5 million shares of common stock at Wednesday's closing price of $10.42 per share, a discount of just 5.4 percent from Tuesday's closing price of $11.01. Read More

Panel: Flexibility Needed to Tackle What-Ifs of Smallpox

WASHINGTON – An FDA advisory committee faced some stark what-ifs this week in developing a treatment for a disease that no longer exists in the natural world. Read More

Orexigen Adding $90M Publicly, Ready for Contrave CVOT Trial

Back in September, Orexigen Therapeutics Inc.'s CEO told BioWorld Today that the firm hoped to avoid a near-term financing by securing an ex-U.S. partnership to help offset costs for the large cardiovascular outcomes trial (CVOT) required by the FDA to get obesity candidate Contrave (naltrexone HCl/buproprion) over the finish line. Read More

Other News To Note

• Dicerna Pharmaceuticals Inc., of Watertown, Mass., said partner Kyowa Hakko Kirin Co. Ltd., of Tokyo, elected to advance the first collaborative oncology candidate from research stage into formal development studies, triggering a $5 million milestone payment. In addition, Kyowa exercised an option to bring a second cancer target into the collaboration. Read More

Stock Movers

Read More

U.S. Patent Disclosures

• Ampio Pharmaceuticals Inc., of Greenwood Village, Colo., received notices for allowance for two patents. The first is directed to a class of compounds combining elements of diketopiperazines and methylphenidate derives, while the second is directed to derivatives of methylphenidate (Ritalin). Read More

Clinic Roundup

• Human Genome Sciences Inc., of Rockville, Md., and GlaxoSmithKline plc, of London, said they started dosing in BLISS-SC, a new Phase III trial of Benlysta (belimumab) administered subcutaneously once weekly to autoantibody-positive adults with active systemic lupus erythematosus (SLE). Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 11, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 12, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 10, 2025
  • Red blood cells in an artery with cholesterol

    In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol

    BioWorld
    In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...
  • Enflonsia

    Merck wins FDA approval in pediatric RSV and steps into CDC uncertainty

    BioWorld
    With the U.S. FDA’s approval of Enflonsia (clesrovimab) to prevent respiratory syncytial virus (RSV) infection lower respiratory tract disease in newborns and...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe